MedCAC meeting
This article was originally published in The Gray Sheet
Executive Summary
Medicare Evidence Development & Coverage Advisory Committee meeting Oct. 21 will review all methods of catheter ablation for the treatment of atrial fibrillation, not just radiofrequency energy-based systems, CMS clarifies Sept. 1 (1"The Gray Sheet" Aug. 24, 2009). Topics on the agenda include clinical comparisons, patient subpopulations, outcomes of interest, and appropriate physician training. MedCAC members will be asked to vote on their levels of confidence that ablation improves health outcomes for longer than one year
You may also be interested in...
MedCAC Sets October Meeting To Debate AF Catheter Ablation Coverage
The Medicare Evidence Development and Coverage Advisory Committee will meet Oct. 21 to see whether evidence shows that treating atrial fibrillation with radiofrequency catheter ablation is safe and effective
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.